von Heymann, Christian
Unverdorben, Martin
Colonna, Paolo
Santamaria, Amparo
Saxena, Manish
Vanassche, Thomas
Köhler, Sabine
Borrow, Amanda P.
Jin, James
Chen, Cathy
Funding for this research was provided by:
Daiichi Sankyo, Inc.
Article History
Received: 10 August 2023
Accepted: 24 November 2023
First Online: 14 December 2023
Declarations
:
: The Global EMIT-AF/VTE programme (NCT02950168, NCT02951039) is a multicentre, prospective, observational programme conducted in accordance with the Declaration of Helsinki and with local Institutional Review Board approvals. All participants provided written informed consent prior to enrolment.
: CvH reports grants and personal fees from Daiichi Sankyo Europe and Daiichi Sankyo Germany; personal fees from Pfizer/Bristol Myers Squibb, CSL Behring, Mitsubishi Pharma, Novo Nordisk Pharma, HICC GbR, Sobi Pharma, and Shionogi Pharma; receipt of a mandate from the German Society of Anaesthesiology and lntensive Care Medicine to write the German Guideline on Preoperative Anaemia; participation in the writing group of the Guideline on Reversal of DOAC-Induced Life-Threatening Bleeding as well as participation in the writing group of the Regional Anaesthesia in Patients on Antithrombotic Drugs (published 2022) both on behalf of the European Society of Anaesthesiology and Intensive Care Medicine; and receipt of a mandate to take part in the writing group of the guidelines on the Diagnostics and Treatment of Peripartum Haemorrhage of the Deutsche Gesellschaft für Gynäkologie und Geburtshilfe. MU, AB, JJ, and CC are employees of Daiichi Sankyo. PC reports grants and personal fees from Daiichi Sankyo Europe; personal fees from Daiichi Sankyo Italy, Boehringer Ingelheim, Bayer AG, and Pfizer/Bristol Myers Squibb; and nonfinancial support from the European Society of Cardiology and the Italian Cardiology Association. AS reports nothing to disclose. MS reports grants and personal fees from Daiichi Sankyo Europe and personal fees from Daiichi Sankyo UK. TV reports grants and personal fees from Daiichi Sankyo Europe; and personal fees from Daiichi Sankyo Be, Bayer, LEO Pharma, and Boehringer Ingelheim. SK reports consulting fees from Daiichi Sankyo.